RAS Mutations Enhance Chemotherapy in AML

Psilocybin May Help Address Cancer-Related Psychological Concerns

The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

Integrating Psilocybin-Assisted Psychotherapy in Comprehensive Cancer Care

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Paolo Tarantino, MD;Matteo Lambertini, MD

January 13th 2025

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.

FDA Approves FoundationOne CDx Diagnostic for Tovorafenib in Brain Tumors

UGN-102 elicited complete responses in 79.6% of patients with non–muscle-invasive bladder cancer at 3 months in the ENVISION trial.

Related Content

Roman Fabbricatore

Psilocybin May Help Address Cancer-Related Psychological Concerns

The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

Integrating Psilocybin-Assisted Psychotherapy in Comprehensive Cancer Care

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Paolo Tarantino, MD;Matteo Lambertini, MD

January 13th 2025

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.